Abstract:Regulated cell death (RCD) is a controlled form of cell death orchestrated by one or more cascading signaling pathways, making it amenable to pharmacological intervention. RCD subroutines can be categorized as apoptotic or non-apoptotic and play essential roles in maintaining homeostasis, facilitating development, and modulating immunity. Accumulating evidence has recently revealed that RCD evasion is frequently the primary cause of tumor survival. Several non-apoptotic RCD subroutines have garnered attention as promising cancer therapies due to their ability to induce tumor regression and prevent relapse, comparable to apoptosis. Moreover, they offer potential solutions for overcoming the acquired resistance of tumors toward apoptotic drugs. With an increasing understanding of the underlying mechanisms governing these non-apoptotic RCD subroutines, a growing number of small-molecule compounds targeting single or multiple pathways have been discovered, providing novel strategies for current cancer therapy. In this review, we comprehensively summarized the current regulatory mechanisms of the emerging non-apoptotic RCD subroutines, mainly including autophagy-dependent cell death, ferroptosis, cuproptosis, disulfidptosis, necroptosis, pyroptosis, alkaliptosis, oxeiptosis, parthanatos, mitochondrial permeability transition (MPT)-driven necrosis, entotic cell death, NETotic cell death, lysosome-dependent cell death, and immunogenic cell death (ICD). Furthermore, we focused on discussing the pharmacological regulatory mechanisms of related small-molecule compounds. In brief, these insightful findings may provide valuable guidance for investigating individual or collaborative targeting approaches towards different RCD subroutines, ultimately driving the discovery of novel small-molecule compounds that target RCD and significantly enhance future cancer therapeutics.

Small molecules targeting tumor apoptosis related proteins and genes

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Bcl-2 Family Proteins As Targets for Anticancer Drug Design

The chemical biology of apoptosis: Revisited after 17 years

Targeting Cellular Apoptotic Pathway with Peptides from Marine Organisms

Targeting Apoptotic and Autophagic Pathways for Cancer Therapeutics

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics

Non-apoptotic cell death in malignant tumor cells and natural compounds

Apoptosis: A Target for Anticancer Therapy

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

B-cell Lymphoma-2 Family Proteins in the Crosshairs: Small Molecule Inhibitors and Activators for Cancer Therapy.

Network Analysis Identifies Drug Targets and Small Molecules to Modulate Apoptosis Resistant Cancers

Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis

Small Mitochondria-Targeting Molecules As Anti-Cancer Agents

Targeting Apoptotic Pathway of Cancer Cells with Phytochemicals and Plant-Based Nanomaterials

The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death

Intrinsically Connected: Therapeutically Targeting the Cathepsin Proteases and the Bcl-2 Family of Protein Substrates as Co-regulators of Apoptosis

Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine

Cell death pathways: molecular mechanisms and therapeutic targets for cancer